Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07HRU
|
|||
| Former ID |
DCL000355
|
|||
| Drug Name |
KRN633
|
|||
| Synonyms |
KRN-633; VEGF Receptor Tyrosine Kinase Inhibitor III, KRN633; KRN633, KRN-633, KRN 633; N-(2-Chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N′-propylurea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glioma [ICD-11: 2A00.0] | Phase 1 | [1], [2] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Kirin
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H21ClN4O4
|
|||
| Canonical SMILES |
CCCNC(=O)NC1=C(C=C(C=C1)OC2=NC=NC3=CC(=C(C=C32)OC)OC)Cl
|
|||
| InChI |
1S/C20H21ClN4O4/c1-4-7-22-20(26)25-15-6-5-12(8-14(15)21)29-19-13-9-17(27-2)18(28-3)10-16(13)23-11-24-19/h5-6,8-11H,4,7H2,1-3H3,(H2,22,25,26)
|
|||
| InChIKey |
VPBYZLCHOKSGRX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 286370-15-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14720360, 14806768, 23984867, 26759727, 44692624, 51897954, 53800456, 103567372, 104253211, 124757337, 125164141, 134339007, 136348252, 136367547, 142749305, 152258380, 160647217, 160854732, 162011869, 162037666, 162202674, 163679255, 163687135, 163907982, 172919154, 174006598, 174528673, 175426544, 178102678, 180372408, 185974477, 208264677, 223395524, 223705286, 223904226, 227478640, 243575836, 249814488, 251910663, 252215651
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6057). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017407) | |||
| REF 3 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.